Antitrust & Price-Fixing Litigation

D&G has served as Lead Counsel or in similar leadership positions on behalf of our business clients in a number of antitrust cases across the nation. Our cases may involve horizontal price-fixing, monopolization, price discrimination or other anticompetitive conduct, and have involved construction products, pesticides, and misuse of patent litigation to keep competitors out of the market in the pharmaceuticals industry. For more information regarding our antitrust practice, contact David Guin, John Wylie or Tammy Stokes.

Some of our cases have included the following:

In re OSB Antitrust Litigation

David Guin and Tammy Stokes are Class Counsel in this case alleging price-fixing by the manufacturers of “oriented strand board,” a plywood substitute. For recent news on this pending litigation, » click here.

Blue Cross and Blue Shield of Alabama, et al v. BASF Corporation (Synthroid® Marketing Litigation).

Our firm was appointed Co-Lead Counsel for a class of third-party payors (“TPPs”), including health insurers, managed care organizations, and self-funded health benefit plans that alleged that the defendants’ illegal marketing practices cause the TPPs to be overcharged for Synthroid®, a thyroid medication.

United Wisconsin Services, Inc., et al. v. Mylan Laboratories, Inc., et al. (Lorazepam Marketing Litigation).

Our firm served as counsel for a proposed class of third-party payors (“TPPs”), includinghealth insurers, managed care organizations, and self-funded health benefit plans, that have alleged that the defendants have conspired to establish and maintain an illegal monopoly in the generic lorazepam and clorazepate dipotassium markets in violation ofantitrust laws. The TPPs claim damages caused by the absence of competition in the markets for lorazepam (generic form of Ativan®) and clorazepate dipotassium (generic form of Tranxene®), two anti-anxiety drugs.